-
1
-
-
33845444046
-
Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
-
(2006)
N Engl J Med
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
-
2
-
-
80053361301
-
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
-
Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657-60.
-
(2011)
Blood
, vol.118
, Issue.13
, pp. 3657-3660
-
-
Chomel, J.C.1
Bonnet, M.L.2
Sorel, N.3
Bertrand, A.4
Meunier, M.C.5
Fichelson, S.6
-
3
-
-
81555214617
-
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
-
Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118 (20):5565-72.
-
(2011)
Blood
, vol.118
, Issue.20
, pp. 5565-5572
-
-
Chu, S.1
McDonald, T.2
Lin, A.3
Chakraborty, S.4
Huang, Q.5
Snyder, D.S.6
-
4
-
-
33744486584
-
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
-
Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532-9.
-
(2006)
Blood
, vol.107
, Issue.11
, pp. 4532-4539
-
-
Copland, M.1
Hamilton, A.2
Elrick, L.J.3
Baird, J.W.4
Allan, E.K.5
Jordanides, N.6
-
5
-
-
77950959714
-
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity
-
Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010;24(4):765-70.
-
(2010)
Leukemia.
, vol.24
, Issue.4
, pp. 765-770
-
-
Engler, J.R.1
Frede, A.2
Saunders, V.A.3
Zannettino, A.C.4
Hughes, T.P.5
White, D.L.6
-
6
-
-
34247555482
-
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
-
Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926-35.
-
(2007)
Leukemia
, vol.21
, Issue.5
, pp. 926-935
-
-
Jiang, X.1
Zhao, Y.2
Smith, C.3
Gasparetto, M.4
Turhan, A.5
Eaves, A.6
-
7
-
-
67650607999
-
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
-
Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25): 6322-9.
-
(2009)
Blood
, vol.113
, Issue.25
, pp. 6322-6329
-
-
Kantarjian, H.1
Cortes, J.2
Kim, D.W.3
Dorlhiac-Llacer, P.4
Pasquini, R.5
DiPersio, J.6
-
8
-
-
73949105873
-
Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations
-
Muller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944-53.
-
(2009)
Blood
, vol.114
, Issue.24
, pp. 4944-4953
-
-
Muller, M.C.1
Cortes, J.E.2
Kim, D.W.3
Druker, B.J.4
Erben, P.5
Pasquini, R.6
-
9
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
-
(2010)
N Engl J Med
, vol.362
, Issue.24
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
10
-
-
57149097077
-
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells
-
Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23):9624-33.
-
(2008)
Cancer Res.
, vol.68
, Issue.23
, pp. 9624-9633
-
-
Konig, H.1
Copland, M.2
Chu, S.3
Jove, R.4
Holyoake, T.L.5
Bhatia, R.6
-
11
-
-
52449100460
-
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications
-
Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 2008;14(12):3881-8.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.12
, pp. 3881-3888
-
-
Hiwase, D.K.1
Saunders, V.2
Hewett, D.3
Frede, A.4
Zrim, S.5
Dang, P.6
-
12
-
-
54049128527
-
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia
-
Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008;112(8):3348-54.
-
(2008)
Blood.
, vol.112
, Issue.8
, pp. 3348-3354
-
-
Giannoudis, A.1
Davies, A.2
Lucas, C.M.3
Harris, R.J.4
Pirmohamed, M.5
Clark, R.E.6
-
13
-
-
70350132811
-
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties
-
Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009;158(4):1153-64.
-
(2009)
Br J Pharmacol
, vol.158
, Issue.4
, pp. 1153-1164
-
-
Hegedus, C.1
Ozvegy-Laczka, C.2
Apati, A.3
Magocsi, M.4
Nemet, K.5
Orfi, L.6
-
14
-
-
0028024938
-
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia
-
ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood. 1994;84(6):1731-6.
-
(1994)
Blood.
, vol.84
, Issue.6
, pp. 1731-1736
-
-
Ten Hoeve, J.1
Arlinghaus, R.B.2
Guo, J.Q.3
Heisterkamp, N.4
Groffen, J.5
-
15
-
-
0028142490
-
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia
-
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269(37):22925-8.
-
(1994)
J Biol Chem.
, vol.269
, Issue.37
, pp. 22925-22928
-
-
Oda, T.1
Heaney, C.2
Hagopian, J.R.3
Okuda, K.4
Griffin, J.D.5
Druker, B.J.6
-
16
-
-
67349280901
-
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
-
Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol. 2009;37(6):692-700.
-
(2009)
Exp Hematol.
, vol.37
, Issue.6
, pp. 692-700
-
-
Hatziieremia, S.1
Jordanides, N.E.2
Holyoake, T.L.3
Mountford, J.C.4
Jorgensen, H.G.5
-
17
-
-
70450255111
-
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
-
Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009;23(11):1999-2006.
-
(2009)
Leukemia
, vol.23
, Issue.11
, pp. 1999-2006
-
-
Davies, A.1
Jordanides, N.E.2
Giannoudis, A.3
Lucas, C.M.4
Hatziieremia, S.5
Harris, R.J.6
-
18
-
-
65649084180
-
Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
-
Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009;78(2): 153-61.
-
(2009)
Biochem Pharmacol
, vol.78
, Issue.2
, pp. 153-161
-
-
Tiwari, A.K.1
Sodani, K.2
Wang, S.R.3
Kuang, Y.H.4
Ashby Jr., C.R.5
Chen, X.6
-
19
-
-
77954892297
-
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib
-
Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010;38(8):1371-80.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.8
, pp. 1371-1380
-
-
Dohse, M.1
Scharenberg, C.2
Shukla, S.3
Robey, R.W.4
Volkmann, T.5
Deeken, J.F.6
-
20
-
-
77949424637
-
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: Implications for combination TKI therapy
-
Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia. 2010;24(3):658-60.
-
(2010)
Leukemia.
, vol.24
, Issue.3
, pp. 658-660
-
-
Hiwase, D.K.1
White, D.2
Zrim, S.3
Saunders, V.4
Melo, J.V.5
Hughes, T.P.6
|